3625 results for «248»
3625 results
Treatment of paravalvular leak
21 Nov 2023 – From PCR London Valves 2023
Explore innovative approaches in paravalvular leak management with this selection of cases: discover the unique strategy of employing three plugs to close a challenging mitral paravalvular leak, navigate the challenges of tackling device migration and retrieval in the closure of a sizable aortic paravalvular leak, gain...
Mitral valve interventions in challenging clinical situations
21 Nov 2023 – From PCR London Valves 2023
Discover innovative approaches to mitral valve interventions in challenging clinical situations: navigate the challenges of critical stenosis in a bioprosthetic mitral valve, learn more about the use of iVAC-2L in transcatheter edge-to-edge repair for a mitral valve lacking leaflet coaptation, explore mitral transcutaneous edge-to-edge repair guided by transthoracic...
Second time TAVI (TAV-in-TAV) - Not as simple as it looks
19 Nov 2023 – From PCR London Valves 2023
Although it is still rare, TAV-in-TAV is likely to become more frequent, as TAVI is increasingly implanted in younger patients. Harmonizing data in this area will therefore help to improve outcomes, the quality of which depends on site experience, bearing in mind that for the time...
RESHAPE-HF2 - Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure
01 Sep 2024
Nicola Ryan provides her take on the RESHAPE-HF2 trial presented by Stefan Anker at the ESC Congress 2024 in London and simultaneously published in the NEJM.
The RESHAPE-HF 2 trial is a prospective randomised control trial comparing transcatheter mitral valve repair (TEER) and guideline-directed medical therapy to guideline-directed medical...
Author
Insights from the Corevalve US Pivotal and SURTAVI trials
05 Apr 2022
Pierre Deharo and Giuseppe Di Gioia provide their take on this analysis of the 5 years incidence, outcomes and predictors of hemodynamic SVD in patients undergoing TAVI and surgery from the Corevalve US Pivotal and SURTAVI trials.
Author
Author
